Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing–remitting multiple sclerosis patients: a monocentric longitudinal observational study — Chiara Zanetta (2023) | RDL Network
Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing–remitting multiple sclerosis patients: a monocentric longitudinal observational study
Article 2023 en
Authors
CZ
Chiara Zanetta
MR
Maria A. Rocca
AM
Alessandro Meani
Abstract
1 min read
Our study confirms previous data on cladribine effectiveness and safety. Cladribine is more effective when placed early in the treatment algorithm. Real-world data on larger populations with longer follow-up are needed to confirm our findings.
Discussion(0)
No comments yet. Be the first to comment.